Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05532722Phase 1Completed

ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

Role: lead

NCT05721573Phase 2Completed

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Role: lead

NCT06450886Phase 2Active Not Recruiting

Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis

Role: lead

NCT04659031Phase 1Completed

A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)

Role: lead

All 4 trials loaded